Foghorn Therapeutics (FHTX) News
NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.72-0.06 (-3.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FHTX news summary
We found 3 recent headlines mentioning Foghorn Therapeutics (FHTX): 0 in the past week and 3 in the past 30 days, most often from PR Newswire, GlobeNewswire. For price context, FHTX is down 3.37% at $1.72. The most recent story, "Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update", was published by GlobeNewswire on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Foghorn Therapeutics headlines
- Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are…PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are…PR Newswire